triazoles has been researched along with choline salicylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abeykoon, JP; Boughey, JC; Boysen, J; Carr, RM; Couch, FJ; Dasari, S; Feldman, AL; Goetz, MP; Hou, X; Hu, C; Kapoor, P; King, RL; Kumar, S; Manske, MK; Mladek, AC; Molina, JR; Nowakowski, KE; Paludo, J; Parikh, SA; Patnaik, MM; Phillips, JL; Ravindran, A; Robinson, SI; Sarkaria, JN; Stenson, MJ; Wang, L; Weroha, SJ; Witzig, TE; Wu, X; Yu, J | 1 |
1 other study(ies) available for triazoles and choline salicylate
| Article | Year |
|---|---|
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Choline; DNA Repair; DNA Replication; DNA, Neoplasm; Drug Combinations; Drug Synergism; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Phthalazines; Piperazines; Random Allocation; Receptors, Cytoplasmic and Nuclear; S Phase Cell Cycle Checkpoints; Salicylates; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |